These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 728284)

  • 21. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.
    Forssell G; Graffner C; Nordlander R; Nyquist O
    Eur J Clin Pharmacol; 1980; 17(3):209-13. PubMed ID: 7363933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
    Lima JJ; Haughey DB; Leier CV
    J Pharmacokinet Biopharm; 1984 Jun; 12(3):289-313. PubMed ID: 6502472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disopyramide kinetics in renal impairment: determinants of interindividual variability.
    Burk M; Peters U
    Clin Pharmacol Ther; 1983 Sep; 34(3):331-40. PubMed ID: 6883909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics of disopyramide in patients with acute myocardial infarction.
    Jounela AJ; Pentikäinen PJ; Oksanen K
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):276-82. PubMed ID: 7107076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
    Lima JJ; Boudoulas H; Blanford M
    J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man.
    Thibonnier M; Holford NH; Upton RA; Blume CD; Williams RL
    J Pharmacokinet Biopharm; 1984 Dec; 12(6):559-73. PubMed ID: 6398364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiarrhythmic and electrocardiographic effects of single oral doses of disopyramide.
    Hulting J; Jansson B
    Eur J Clin Pharmacol; 1977 Jan; 11(2):91-9. PubMed ID: 320015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative absorption of disopyramide as determined by liquid chromatography following acute administration of standard capsules and controlled-release tablets.
    Graffner C; Lagerström PO; Lundborg PN; Rönn OF
    Int J Clin Pharmacol Ther Toxicol; 1981 Sep; 19(9):414-9. PubMed ID: 7298249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition kinetics of disopyramide in human healthy volunteers described by an open three compartment model.
    Bonde J; Jensen NM; Pedersen LE; Angelo HR; Rasmussen SN; Trap-Jensen J; Kampmann JP
    Pharmacol Toxicol; 1989 May; 64(5):412-6. PubMed ID: 2771866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.
    Bonde J; Angelo HR; Bødtker S; Svendsen TL; Kampmann JP
    Acta Pharmacol Toxicol (Copenh); 1985 Apr; 56(4):278-82. PubMed ID: 4024955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of Norpace.
    Karim A
    Angiology; 1975 Jan; 26(1 Pt 2):85-98. PubMed ID: 1090217
    [No Abstract]   [Full Text] [Related]  

  • 32. Disopyramide pharmacokinetics in patients with acute myocardial infarction.
    Pentikäinen PJ; Huikuri H; Jounela AJ; Wilen G
    Eur J Clin Pharmacol; 1985; 28(1):45-51. PubMed ID: 3987785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the bioavailability of two slow release preparations of disopyramide.
    Bogaert MG; Belpaire F; De Wilde G; Lefebvre RA
    Eur J Clin Pharmacol; 1991; 40(6):629-30. PubMed ID: 1884747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral disopyramide dosage regimes in ischaemic heart disease.
    Bryson SM; Fotheringham GH; Struthers MG; Whiting B
    J Clin Hosp Pharm; 1982 Mar; 7(1):37-42. PubMed ID: 7096577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.
    Lien E; Bakke OM
    Br J Clin Pharmacol; 1983 Jul; 16(1):71-6. PubMed ID: 6882625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical studies of the antiarrhythmic efficacy of disopyramide phosphate (Norpace) (author's transl)].
    Smith WS
    Herz; 1978 Dec; 63(36):399-406. PubMed ID: 95482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.
    Upton RA; Williams RL
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):365-79. PubMed ID: 3772738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of disopyramide in patients with chronic renal failure.
    Francois B; Mallein R; Rondelet J; Lussignol M
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-arrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia.
    Hulting J; Rosenhamer G
    J Int Med Res; 1976; 4(1 Suppl):90-5. PubMed ID: 1026537
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
    Johnston A; Henry JA; Warrington SJ; Hamer NA
    Br J Clin Pharmacol; 1980 Sep; 10(3):245-8. PubMed ID: 7437241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.